A novel mRNA-based vaccine approach targeting respiratory syncytial virus has demonstrated 82 percent efficacy in preventing severe RSV disease in infants under six months in a large Phase 3 trial, a population for which no vaccine has previously achieved sufficient efficacy and safety to support regulatory approval. RSV is the leading cause of infant hospitalization in the United States and globally, making an effective infant vaccine one of the most significant potential public health advances in pediatric medicine.
The vaccine works through maternal immunization, with pregnant women vaccinated in the third trimester generating antibodies that cross the placenta and protect newborns during their most vulnerable period. A second product using this approach from a different manufacturer is also in late-stage trials, potentially creating competition that would improve accessibility and pricing. The FDA is expected to complete review of the lead candidate within the next six months.
